LAVA Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
LAVA Therapeutics has a total shareholder equity of $51.2M and total debt of $5.3M, which brings its debt-to-equity ratio to 10.3%. Its total assets and total liabilities are $101.7M and $50.5M respectively.
Key information
10.3%
Debt to equity ratio
US$5.28m
Debt
| Interest coverage ratio | n/a |
| Cash | US$95.57m |
| Equity | US$51.18m |
| Total liabilities | US$50.53m |
| Total assets | US$101.71m |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: LVTX's short term assets ($98.9M) exceed its short term liabilities ($14.9M).
Long Term Liabilities: LVTX's short term assets ($98.9M) exceed its long term liabilities ($35.6M).
Debt to Equity History and Analysis
Debt Level: LVTX has more cash than its total debt.
Reducing Debt: Insufficient data to determine if LVTX's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: LVTX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: LVTX has sufficient cash runway for 2.9 years if free cash flow continues to grow at historical rates of 5.4% each year.